“As part of our enhanced surveillance of thromboembolic disorders, 3 new cases of thrombosis of the large veins of atypical locations associated with thrombocytopenia and/or coagulation disorders were analyzed during the weekly monitoring committee of the ANSM with the network French CRPVs (12 cases in total since the start of vaccination, including 4 deaths).
These cases, mainly located in the brain, occurred within a median time of 9 days after vaccination, mainly in women and with no specific common history identified to date (9 vaccinated people under 55 years old, 3 people over 55 years).”
ANSM reportThe seventh pharmacovigilance report on adverse reactions reported with the AstraZeneca vaccine (Vaxzevria) covers data validated from March 19 to 25, 2021
Information from the previous (sixth) ANSM report:
“The sixth pharmacovigilance report on adverse reactions reported with the AstraZeneca vaccine covers data validated from March 12 to March 18, 2021 . Since the start of vaccination with the AstraZeneca vaccine, 5,693 cases of adverse effects have been analyzed by the CRPV reporters (Amiens and Rouen). The vast majority of these cases concern flu-like syndromes, often of high intensity (high fever, body aches, headaches). More than 1,430,000 injections have been performed as of March 18, 2021.
As part of our enhanced surveillance of thromboembolic disorders, a total of 16 new cases were analyzed during the weekly ANSM monitoring committee with the French CRPV network, for a total of 29 cases since the start of vaccination. The majority of thromboembolic events have occurred within 15 days of vaccination in patients with risk factors.
Among all these cases, 9 cases of thrombosis of the large veins, atypical by their location (mainly cerebral, but also digestive), which may be associated with thrombocytopenia or coagulation disorders were reported, including 2 deaths. These cases occurred within a median of 8.5 days after vaccination in people with no specific history identified to date (7 patients under 55 years old, 2 patients over 55 years old).”
ANSM report The sixth pharmacovigilance report on adverse reactions reported with the AstraZeneca vaccine covers data validated from March 12 to March 18, 2021
** This post was originally published on April 3, 2021 **
